Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $377
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $338 to $377.
March 15, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Madrigal Pharmaceuticals and raises the price target from $338 to $377.
The increase in price target by Canaccord Genuity reflects a positive outlook on Madrigal Pharmaceuticals, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100